What a post!
Just on that failed Phase 2a trial for Lorecivivint, the primary endpoint was pain score and no dose showed statistical significance against placebo. The researchers, as is their wont, looked for silver linings - but Dr David Felson was not having any of it...
Bang!
https://www.medpagetoday.com/rheumatology/arthritis/86677
- Forums
- ASX - By Stock
- Trial PAR008 is on ANZCTR
What a post!Just on that failed Phase 2a trial for Lorecivivint,...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
|
|||||
Last
23.0¢ |
Change
0.010(4.55%) |
Mkt cap ! $80.45M |
Open | High | Low | Value | Volume |
22.8¢ | 23.3¢ | 22.5¢ | $46.92K | 203.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 337 | 23.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 138166 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 337 | 0.230 |
4 | 84610 | 0.225 |
14 | 174871 | 0.220 |
6 | 73458 | 0.215 |
5 | 131050 | 0.210 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 138166 | 5 |
0.250 | 15000 | 1 |
0.260 | 26050 | 3 |
0.270 | 13000 | 2 |
0.275 | 10000 | 1 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |